It will head higher in the coming months. They have the MAA to file for rivo-cel pediatric blood disorders in late 2019 and then multi dose rimiducid for BPX-601 pancreatic cancer in late 2019. Based on these catalysts I believe the run is not yet over.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.